Search

Your search keyword '"van Norden, Yvette"' showing total 159 results
Start Over Author "van Norden, Yvette"
159 results on '"van Norden, Yvette"'

5. Benefits and risks of clofarabine in adult acute lymphoblastic leukemia investigated in depth by multi‐state modeling

Author

Hermans, Sjoerd J. F., primary, van Norden, Yvette, additional, Versluis, Jurjen, additional, Rijneveld, Anita W., additional, van der Holt, Bronno, additional, de Weerdt, Okke, additional, Biemond, Bart J., additional, van de Loosdrecht, Arjan A., additional, van der Wagen, Lotte E., additional, Bellido, Mar, additional, van Gelder, Michel, additional, van der Velden, Walter J. F. M., additional, Selleslag, Dominik, additional, van Lammeren‐Venema, Daniëlle, additional, van der Velden, Vincent H. J., additional, de Wreede, Liesbeth C., additional, Postmus, Douwe, additional, Pignatti, Francesco, additional, and Cornelissen, Jan J., additional

Published
2024
Full Text
View/download PDF

6. Response to the letter-to-the-editor “Comments on: Accounting for fractionation and heterogeneous dose distributions in the modelling of osteoradionecrosis in oropharyngeal carcinoma treatment’’

Author

Verduijn, Gerda M., primary, Sijtsema, Nienke D., additional, van Norden, Yvette, additional, Heemsbergen, Wilma D., additional, Mast, Hetty, additional, Sewnaik, Aniel, additional, Chin, Denzel, additional, Baker, Sarah, additional, Capala, Marta E., additional, van der Lugt, Aad, additional, van Meerten, Esther, additional, Hoogeman, Mischa S., additional, and Petit, Steven F., additional

Published
2023
Full Text
View/download PDF

7. P619: TRACKING DISEASE PARAMETERS BY MRD, CT AND PET IN FIRST LINE CLL PATIENTS TREATED WITH FIXED DURATION IBRUTINIB-VENETOCLAX; INTERIM ANALYSIS OF THE FIRST 30 PATIENTS IN HOVON 158/NEXT STEP TRIAL.

Author

Kersting, Sabina, primary, Levin, Mark-David, additional, Dubois, Julie, additional, van Norden, Yvette, additional, Dobber, Johan, additional, Jauw, Yvonne, additional, van der Kevie-Kersemaekers, Anne-Marie, additional, Mellink, Clemens, additional, Da Cunha-Bang, Caspar, additional, Van Desr Burg, Leonie, additional, Te Raa, Doreen, additional, de Boer, Fransien, additional, Droogendijk, Jolanda, additional, Idink, Cecile, additional, De Heer, Koen, additional, Nijziel, Marten, additional, Tick, Lidwine, additional, Ludwig, Inge, additional, Silbermann, Mathijs, additional, Beeker, Aart, additional, Bellido, Mar, additional, Evers, Ludo, additional, Zwezerijnen, Gerben, additional, Zijlstra, Josée, additional, Kap, Marcel, additional, Niemann, Carsten, additional, and Kater, Arnon, additional

Published
2023
Full Text
View/download PDF

8. P565: REAL-WORLD DATA AS SUPPLEMENTARY CONTROLS FOR THE PROSPECTIVE RANDOMIZED HOVON-103 TRIAL IN INTENSIVELY TREATED ELDERLY ACUTE MYELOID LEUKEMIA PATIENTS

Author

Hermans, Sjoerd, primary, van Norden, Yvette, additional, van Werkhoven, Erik, additional, Dinmohamed, Avinash, additional, Huijgens, Peter, additional, Ossenkoppele, Gert, additional, Huls, Gerwin, additional, Löwenberg, Bob, additional, Pabst, Thomas, additional, Breems, Dimitri, additional, Postmus, Douwe, additional, Pignatti, Francesco, additional, Versluis, Jurjen, additional, and Cornelissen, Jan, additional

Published
2023
Full Text
View/download PDF

9. The dynamical U(n) quantum group

Author

Koelink, Erik and van Norden, Yvette

Subjects
Mathematics - Quantum Algebra
Abstract

We study the dynamical analogue of the matrix algebra M(n), constructed from a dynamical R-matrix given by Etingof and Varchenko. A left and a right corepresentation of this algebra, which can be seen as analogues of the exterior algebra representation, are defined and this defines dynamical quantum minor determinants as the matrix elements of these corepresentations. These elements are studied in more detail, especially the action of the comultiplication and Laplace expansions. Using the Laplace expansions we can prove that the dynamical quantum determinant is almost central, and adjoining an inverse the antipode can be defined. This results in the dynamical GL(n) quantum group associated to the dynamical R-matrix. We study a *-structure leading to the dynamical U(n) quantum group, and we obtain results for the canonical pairing arising from the R-matrix., Comment: 24 pages

Published
2005

10. Pairings and actions for dynamical quantum groups

Author

Koelink, Erik and van Norden, Yvette

Subjects
Mathematics - Quantum Algebra
Abstract

Dynamical quantum groups constructed from a FRST-construction using a solution of the quantum dynamical Yang-Baxter equation are equipped with a natural pairing. The interplay of the pairing with *-structures, (unitarizable) corepresentations and dynamical representations is studied, and natural left and right actions are introduced. Explicit details for the elliptic U(2) dynamical quantum group corresponding to the elliptic R-matrix for sl(2) are given, and the pairing is calculated explicitly in terms of elliptic hypergeometric functions. Dynamical analogues of spherical and singular vectors for corepresentations are introduced., Comment: 32 pages

Published
2004

11. Elliptic U(2) quantum group and elliptic hypergeometric series

Author

Koelink, Erik, van Norden, Yvette, and Rosengren, Hjalmar

Subjects
Mathematics - Quantum Algebra, Mathematics - Representation Theory
Abstract

We investigate an elliptic quantum group introduced by Felder and Varchenko, which is constructed from the $R$-matrix of the Andrews-Baxter-Forrester model, containing both spectral and dynamical parameter. We explicitly compute the matrix elements of certain corepresentations and obtain orthogonality relations for these elements. Using dynamical representations these orthogonality relations give discrete bi-orthogonality relations for terminating very-well-poised balanced elliptic hypergeometric series, previously obtained by Frenkel and Turaev and by Spiridonov and Zhedanov in different contexts., Comment: 20 pages

Published
2003
Full Text
View/download PDF

14. Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML

Author

Löwenberg, Bob, Pabst, Thomas, Maertens, Johan, van Norden, Yvette, Biemond, Bart J., Schouten, Harry C., Spertini, Olivier, Vellenga, Edo, Graux, Carlos, Havelange, Violaine, de Greef, Georgine E., de Weerdt, Okke, Legdeur, Marie-Cecile J.C., Kuball, Juergen, Kooy, Marinus van Marwijk, Gjertsen, Bjorn T., Jongen-Lavrencic, Mojca, van de Loosdrecht, Arjan A., van Lammeren-Venema, Daniëlle, Hodossy, Beata, Breems, Dimitri A., Chalandon, Yves, Passweg, Jakob, Valk, Peter J.M., Manz, Markus G., and Ossenkoppele, Gert J.

Published
2017
Full Text
View/download PDF

15. Prediction of Nonrelapse Mortality in Patients with Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Receiving Allogeneic Stem Cell Transplantation with Posttransplantation Cyclophosphamide-based Graft Versus Host Disease Prophylaxis

Author

Hermans, Sjoerd J. F., Versluis, Jurjen, Labopin, Myriam, Giebel, Sebastian, van Norden, Yvette, Moiseev, Ivan, Blaise, Didier, Díez Martín, Jose L., Meijer, Ellen, Rovira, Montserrat, Choi, Goda, Raiola, Anna Maria, Koc, Yener, Reményi, P. ter, Vydra, Jan, Kröger, Nicolaus, Sica, Simona, Martino, Massimo, van Gorkom, Gwendolyn, Chevallier, Patrice, Busca, Alessandro, Herrera Arroyo, Concepcion, Brissot, Eolia, Peric, Zinaida, Nagler, Arnon, Shouval, Roni, Ciceri, Fabio, Cornelissen, Jan J., Mohty, Mohamad, Hematology, AII - Inflammatory diseases, CCA - Cancer Treatment and quality of life, CCA - Imaging and biomarkers, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, and MUMC+: MA Hematologie (9)

Subjects
SCORING SYSTEMS, Settore MED/15 - MALATTIE DEL SANGUE, HIGH-RISK, COMORBIDITY INDEX, DIAGNOSIS TRIPOD, Hematology, NON-RELAPSE MORTALITY, INDIVIDUAL PROGNOSIS, CARDIAC TOXICITY, BONE-MARROW-TRANSPLANTATION, SINGLE-AGENT, PREVENTION, Prediction of Nonrelapse Mortality in Patients With Acute Myeloid Leukemia and Acute Lymphoblastic
Abstract

Graft versus host disease (GVHD) prophylaxis with posttransplantation cyclophosphamide (PTCY) has been established to reduce severe GVHD, and thereby potentially reducing nonrelapse mortality (NRM) after allogeneic stem cell transplantation (alloSCT). We evaluated the predictive capacity of established NRM-risk scores in patients receiving PTCY-based GVHD prophylaxis, and subsequently developed and validated a novel PTCY-specific NRM-risk model. Adult patients (n = 1861) with AML or ALL in first complete remission who received alloSCT with PTCY-based GVHD prophylaxis were included. The PTCY-risk score was developed using multivariable Fine and Gray regression, selecting parameters from the hematopoietic cell transplantation-comorbidity index (HCT-CI) and European Group for Blood and Marrow Transplantation (EBMT) score with a subdistribution hazard ratio (SHR) of >= 1.2 for 2-year NRM in the training set (70% split), which was validated in the test set (30%). The performance of the EBMT score, HCT-CI, and integrated EBMT score was relatively poor for discriminating 2-year NRM (c-statistic 51.7%, 56.6%, and 59.2%, respectively). The PTCY-risk score included 10 variables which were collapsed in 3 risk groups estimating 2-year NRM of 11% +/- 2%, 19% +/- 2%, and 36% +/- 3% (training set, c-sta-tistic 64%), and 11% +/- 2%, 18% +/- 3%, and 31% +/- 5% (test set, c-statistic 63%), which also translated into different overall survival. Collectively, we developed an NRM-risk score for acute leukemia patients receiving PTCY that better predicted 2-year NRM compared with existing models, which might be applicable to the specific toxicities of high-dose cyclophosphamide.

Published
2023

17. Post radiation mucosal ulcer risk after a hypofractionated stereotactic boost and conventional fractionated radiotherapy for oropharyngeal carcinoma

Author

Verduijn, Gerda M., primary, Petit, Steven F., additional, Lauwers, Iris, additional, van Norden, Yvette, additional, Sijtsema, Nienke D., additional, Sewnaik, Aniel, additional, Mast, Hetty, additional, Capala, Marta, additional, Nout, Remi, additional, Baker, Sarah, additional, van Meerten, Esther, additional, Hoogeman, Mischa S., additional, van der Lugt, Aad, additional, and Heemsbergen, Wilma D., additional

Published
2022
Full Text
View/download PDF

21. The COMPLETE trial: HolistiC early respOnse assessMent for oroPharyngeaL cancEr paTiEnts; Protocol for an observational study

Author

Verduijn, Gerda M, primary, Capala, Marta E, additional, Sijtsema, Nienke D, additional, Lauwers, Iris, additional, Hernandez Tamames, Juan A, additional, Heemsbergen, Wilma D, additional, Sewnaik, Aniel, additional, Hardillo, Jose A, additional, Mast, Hetty, additional, van Norden, Yvette, additional, Jansen, Maurice P H M, additional, van der Lugt, Aad, additional, van Gent, Dik C, additional, Hoogeman, Mischa S, additional, Mostert, Bianca, additional, and Petit, Steven F, additional

Published
2022
Full Text
View/download PDF

22. Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK)

Author

Ossenkoppele, Gert J., Stussi, Georg, Maertens, Johan, van Montfort, Kees, Biemond, Bart J., Breems, Dimitri, Ferrant, August, Graux, Carlos, de Greef, Georgine E., Halkes, C. J.M., Hoogendoorn, Mels, Hollestein, Rene M., Jongen-Lavrencic, Mojca, Levin, Mark D., van de Loosdrecht, Arjan A., van Marwijk Kooij, Marinus, van Norden, Yvette, Pabst, Thomas, Schouten, Harry C., Vellenga, Edo, Verhoef, Gregor E.G., de Weerdt, Okke, Wijermans, Pierre, Passweg, Jakob R., and Löwenberg, Bob

Published
2012
Full Text
View/download PDF

23. Post radiation mucosal ulcer risk after a hypofractionated stereotactic boost and conventional fractionated radiotherapy for oropharyngeal carcinoma.

Author

Verduijn, Gerda M., Petit, Steven F., Lauwers, Iris, van Norden, Yvette, Sijtsema, Nienke D., Sewnaik, Aniel, Mast, Hetty, Capala, Marta, Nout, Remi, Baker, Sarah, van Meerten, Esther, Hoogeman, Mischa S., van der Lugt, Aad, and Heemsbergen, Wilma D.

Subjects
CANKER sores, MULTIPLE regression analysis, OROPHARYNGEAL cancer, HEAD & neck cancer, RETROSPECTIVE studies, ACQUISITION of data, RISK assessment, CANCER patients, COMPARATIVE studies, MEDICAL records, RADIATION doses, DESCRIPTIVE statistics, RADIOSURGERY, RADIATION injuries, ORAL mucosa, PROGRESSION-free survival, SQUAMOUS cell carcinoma, LONGITUDINAL method, PROPORTIONAL hazards models, DISEASE risk factors
Abstract

Post radiation mucosal ulcers (PRMU) after treatment for oropharyngeal squamous cell carcinoma (OPSCC) can have a huge negative impact on patients' quality of life, but little is known concerning risk factors and the impact of fraction size. Therefore, the goal of this study was to determine the pattern of PRMU development and to identify risk factors after a hypofractionated stereotactic body radiotherapy boost (SBRT) compared to conventionally fractionated radiotherapy for OPSCC. We performed a retrospective cohort study (N = 332) of OPSCC patients with ≥ 1-year disease-free survival, treated with 46 Gy Intensity Modulated Radiotherapy (IMRT) (2 Gy fractions) followed by either an SBRT boost of 16.5 Gy (5.5 Gy fractions) (N = 180), or 24 Gy IMRT (2 Gy fractions) (N = 152). PRMU (grade ≥ 2) was scored when observed > three months after the last radiotherapy (RT) fraction (CTCAE v5.0). Potential risk factors were analyzed with Cox regression models using death as competing risk. Dose at the PRMU site was calculated by projecting delineated PRMU on the planning CT. All cases of PRMU (N = 64) occurred within 24 months; all were grade 2. The cumulative incidence at 2 years in the SBRT boost group was 26% (N = 46) vs. 12% (N = 18) for conventional fractionation (p = 0.003). Most PRMU developed within nine months (N = 48). PRMU occurring > nine months (N = 16) were mainly observed in the SBRT boost group (N = 15). Sex (p = 0.048), acute tube feeding (p = < 0.001), tumor subsite tonsil (p = 0.001), and N stage (p = 0.017) were associated with PRMU risk at multivariable regression in the hypofractionated SBRT boost group. All 25 delineated PRMU were located within the high dose regions. The risk of PRMU should be included in the cost benefit analysis when considering future research using a hypofractionated SBRT boost for OPSCC patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

24. Stereotactic Body Radiation Therapy after Chemotherapy for Unresectable Perihilar Cholangiocarcinoma: The STRONG Trial, a Phase I Safety and Feasibility Study

Author

Baak, Rogier, primary, Willemssen, François E. J. A., additional, van Norden, Yvette, additional, Eskens, Ferry A. L. M., additional, Milder, Maaike T. W., additional, Heijmen, Ben J. M., additional, Koerkamp, Bas Groot, additional, Sprengers, Dave, additional, van Driel, Lydi M. J. W., additional, Klümpen, Heinz-Josef, additional, den Toom, Wilhelm, additional, Koedijk, Merel S., additional, IJzermans, Jan N. M., additional, and Méndez Romero, Alejandra, additional

Published
2021
Full Text
View/download PDF

25. P-64 Incidence and risk factors of osteoradionecrosis of the mandible after modern radiotherapy for oropharyngeal carcinoma

Author

Verduijn, Gerda M., primary, Sijtsema, Nienke D., additional, van Norden, Yvette, additional, Heemsbergen, Wilma D., additional, Mast, Hetty, additional, Sewnaik, Aniel, additional, Hove, Ivo ten, additional, Chin, Denzel, additional, Baker, Sarah, additional, van der Lugt, Aad, additional, Hoogeman, Mischa S., additional, and Petit, Steven, additional

Published
2021
Full Text
View/download PDF

27. B-cell receptor stereotyped subsets and outcome for patients with chronic lymphocytic leukemia in the HOVON 68 trial

Author

Vojdeman, Fie J., primary, Pedersen, Lone B., additional, te Raa, Doreen, additional, Juvonen, Vesa, additional, van Norden, Yvette, additional, Tjønnfjord, Geir E., additional, Kimby, Eva, additional, Itälä-Remes, Maija, additional, Rosenquist, Richard, additional, Langerak, Anton W., additional, Evers, Ludo M., additional, Zenz, Thorsten, additional, Walewski, Jan, additional, van Oers, Marinus H. J., additional, Geisler, Christian H., additional, Kater, Arnon P., additional, and Niemann, Carsten U., additional

Published
2021
Full Text
View/download PDF

29. Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation

Author

Kalin, Burak, primary, van Norden, Yvette, additional, van Gelder, Michel, additional, Breems, Dimitri, additional, Maertens, Johan, additional, Jongen-Lavrencic, Mojca, additional, Broers, Annoek E. C., additional, Braakman, Eric, additional, Grob, Tim, additional, Zeijlemaker, Wendelien, additional, Ossenkoppele, Gert J., additional, Meijer, Ellen, additional, and Cornelissen, Jan J., additional

Published
2020
Full Text
View/download PDF

32. Feasibility and efficacy of addition of individualized dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia

Author

Kater, Arnon P, van Oers, Marinus H J, van Norden, Yvette, van der Straten, Lina, Driessen, Julia, Posthuma, Ward F M, Schipperus, Martinus, Chamuleau, Martine E D, Nijland, Marcel, Doorduijn, Jeanette K, Van Gelder, Michel, Hoogendoorn, Mels, De Croon, Francien, Wittebol, Shulamiet, Kerst, J Martijn, Marijt, Erik W A, Raymakers, Reinier A P, Schaafsma, Martijn R, Dobber, Johan A, Kersting, Sabina A, Levin, Mark-David, and HOVON CLL study group

Subjects
Hematology
Abstract

Lenalidomide has been proven to be effective but with a distinct and difficult to manage toxicity profile in the context of chronic lymphocytic leukemia, potentially hampering combination treatment with this drug. We conducted a phase 1-2 study to evaluate the efficacy and safety of six cycles of chlorambucil (7 mg/m 2 daily), rituximab (375 mg/m 2 cycle 1 and 500 mg/m 2 cycles 2-6) and individually-dosed lenalidomide (escalated from 2.5 mg to 10 mg) (induction-I) in first-line treatment of patients with chronic lymphocytic leukemia unfit for treatment with fludarabine, cyclophosphamide and rituximab. This was followed by 6 months of 10 mg lenalidomide monotherapy (induction-II). Of 53 evaluable patients in phase 2 of the study, 47 (89%) completed induction-I and 36 (68%) completed induction-II. In an intention-to-treat analysis, the overall response rate was 83%. The median progression-free survival was 49 months, after a median follow-up time of 27 months. The 2-and 3-year progression-free survival rates were 58% and 54%, respectively. The corresponding rates for overall survival were 98% and 95%. No tumor lysis syndrome was observed, while tumor flair reaction occurred in five patients (9%, 1 grade 3). The most common hematologic toxicity was grade 3-4 neutropenia, which occurred in 73% of the patients. In conclusion, addition of lenalidomide to a chemotherapy backbone followed by a fixed duration of lenalidomide monotherapy resulted in high remission rates and progression-free survival rates, which seem comparable to those observed with novel drug combinations including novel CD20 monoclonal antibodies or kinase inhibitors. Although lenalidomide-specific toxicity remains a concern, an individualized dose-escalation schedule is feasible and results in an acceptable toxicity profile. EuraCT number: 2010-022294-34.

Published
2019

33. Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL

Author

Kater, Arnon P., primary, Kersting, Sabina, additional, van Norden, Yvette, additional, Dubois, Julie, additional, Dobber, Johan A., additional, Mellink, Clemens H., additional, Evers, Ludo M., additional, Croon-de Boer, Fransien, additional, Schreurs, John, additional, van der Spek, Ellen, additional, Visser, Hein, additional, Idink, Cecile, additional, Wittebol, Shulamiet, additional, Hoogendoorn, Mels, additional, Tonino, Sanne H., additional, Mobasher, Mehrdad, additional, and Levin, Mark-David, additional

Published
2018
Full Text
View/download PDF

34. Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia

Author

Kater, Arnon P., primary, van Oers, Marinus H.J., additional, van Norden, Yvette, additional, van der Straten, Lina, additional, Driessen, Julia, additional, Posthuma, Ward F.M., additional, Schipperus, Martin, additional, Chamuleau, Martine E.D., additional, Nijland, Marcel, additional, Doorduijn, Jeanette K., additional, Van Gelder, Michel, additional, Hoogendoorn, Mels, additional, De Croon, Francien, additional, Wittebol, Shulamiet, additional, Kerst, J. Martijn, additional, Marijt, Erik W.A., additional, Raymakers, Reinier A.P., additional, Schaafsma, Martijn R., additional, Dobber, Johan A., additional, Kersting, Sabina, additional, and Levin, Mark-David, additional

Published
2018
Full Text
View/download PDF

36. Early Post-Transplant Epigenetic Therapy By Panobinostat and Decitabine Followed By Donor Lymphocyte Infusion (DLI): Interim Results of the HOVON-116 Phase I/II Feasibility Study in Poor-Risk AML Recipients of Allogeneic Stem Cell Transplantation (alloHSCT)

Author

Cornelissen, Jan J., primary, van Norden, Yvette, additional, van Gelder, Michel, additional, Breems, Dimitri A., additional, Maertens, Johan, additional, Jongen-Lavrencic, Mojca, additional, Broers, Annoek, additional, Zeerleder, Sacha S., additional, Noens, Lucien, additional, Ossenkoppele, Gert, additional, and Meijer, Ellen, additional

Published
2016
Full Text
View/download PDF

37. Including historical data in the analysis of clinical trials: Is it worth the effort?

Author

van Rosmalen, Joost, Dejardin, David, van Norden, Yvette, Löwenberg, Bob, and Lesaffre, Emmanuel

Subjects
CLINICAL trials, BAYESIAN analysis, META-analysis, ACUTE myeloid leukemia, RANDOMIZED controlled trials
Abstract

Data of previous trials with a similar setting are often available in the analysis of clinical trials. Several Bayesian methods have been proposed for including historical data as prior information in the analysis of the current trial, such as the (modified) power prior, the (robust) meta-analytic-predictive prior, the commensurate prior and methods proposed by Pocock and Murray et al. We compared these methods and illustrated their use in a practical setting, including an assessment of the comparability of the current and the historical data. The motivating data set consists of randomised controlled trials for acute myeloid leukaemia. A simulation study was used to compare the methods in terms of bias, precision, power and type I error rate. Methods that estimate parameters for the between-trial heterogeneity generally offer the best trade-off of power, precision and type I error, with the meta-analytic-predictive prior being the most promising method. The results show that it can be feasible to include historical data in the analysis of clinical trials, if an appropriate method is used to estimate the heterogeneity between trials, and the historical data satisfy criteria for comparability. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

38. Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling

Author

Taskesen, Erdogan, primary, Havermans, Marije, additional, van Lom, Kirsten, additional, Sanders, Mathijs A., additional, van Norden, Yvette, additional, Bindels, Eric, additional, Hoogenboezem, Remco, additional, Reinders, Marcel J. T., additional, Figueroa, Maria E., additional, Valk, Peter J. M., additional, Löwenberg, Bob, additional, Melnick, Ari, additional, and Delwel, Ruud, additional

Published
2014
Full Text
View/download PDF

40. The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA

Author

Schlenk, Richard F., primary, Taskesen, Erdogan, additional, van Norden, Yvette, additional, Krauter, Jürgen, additional, Ganser, Arnold, additional, Bullinger, Lars, additional, Gaidzik, Verena I., additional, Paschka, Peter, additional, Corbacioglu, Andrea, additional, Göhring, Gudrun, additional, Kündgen, Andrea, additional, Held, Gerhard, additional, Götze, Katharina, additional, Vellenga, Edo, additional, Kuball, Juergen, additional, Schanz, Urs, additional, Passweg, Jakob, additional, Pabst, Thomas, additional, Maertens, Johan, additional, Ossenkoppele, Gert J., additional, Delwel, Ruud, additional, Döhner, Hartmut, additional, Cornelissen, Jan J., additional, Döhner, Konstanze, additional, and Löwenberg, Bob, additional

Published
2013
Full Text
View/download PDF

41. Radiotherapy and Hyperthermia for Treatment of Primary Locally Advanced Cervix Cancer: Results in 378 Patients

Author

Franckena, Martine, primary, Lutgens, Ludy C., additional, Koper, Peter C., additional, Kleynen, Catharina E., additional, van der Steen-Banasik, Elsbieta M., additional, Jobsen, Jan J., additional, Leer, Jan Willem, additional, Creutzberg, Carien L., additional, Dielwart, Michel F., additional, van Norden, Yvette, additional, Canters, Richard A.M., additional, van Rhoon, Gerard C., additional, and van der Zee, Jacoba, additional

Published
2009
Full Text
View/download PDF

47. Crash Involvement of Motor Vehicles in Relationship to the Number and Severity of Traffic Offenses. An Exploratory Analysis of Dutch Traffic Offenses and Crash Data.

Author

Goldenbeld, Charles, Reurings, Martine, Van Norden, Yvette, and Stipdonk, Henk

Subjects
TRAFFIC accidents, TRAFFIC violations, STATISTICS, AUTOMOBILE speed, LAW enforcement, DATA analysis, TRAFFIC safety
Abstract

Objective:To establish the statistical relationship between offenses and crashes when the unit of analysis is the vehicle instead of the driver, to show the influence of the severity (e.g., minor speed offenses) on this relationship, and to research whether the form of this relationship is similar in different enforcement contexts. Methods:An exploratory analysis was conducted using Dutch traffic offense and crash data. Crash data included all police-registered crashes involving motorized and registered vehicles in 2009; offense data included all non-criminal traffic offenses registered during 2005–2009 (mostly camera detected). Together these comprise an estimated 97 percent of all traffic offenses registered in this period. The analysis was done on a level of identified vehicles rather than persons. Vehicles involved in crashes were matched to vehicles involved in traffic offenses. The offense frequency distributions of registered crash involved vehicles and a random selection of vehicles was analyzed. Two comparisons were made: (1) privately owned vehicles versus company-owned vehicles and (2) vehicles for which only minor speed offenses were registered versus vehicles for which at least one major speed offense was registered. Results:An increase in traffic offense frequency coincides with a stronger increase in relative crash involvement. This relationship was adequately described by a power function. The slightly more than linear increase in the crash risk for vehicles with only minor speed offenses suggests that minor speed offenses (<10 km/h over the limit) contributed slightly to crashes. This relationship was unlikely to be caused by increased distance traveled only. For vehicles with at least one or more major speed violation an approximately quadratic increase of crash risk with increasing speed offense frequency was found. A comparison of Dutch and Canadian data showed a much more progressive offense–crash relationship in the Dutch data. Conclusion:The crash involvement of vehicles increased more than linearly with the number of minor traffic violations. Thus, automatic detection of minor offenses bears relevance to safety. The substantial increase in crash rates with speed offense frequency for vehicles with at least one major speed violation suggests that these vehicles represent a specific group with a significantly increased crash risk, especially in the case of many minor offenses. The more progressive relationship between offenses and crashes in The Netherlands when compared to Canada was hypothesized to result from the higher intensity camera enforcement levels and less severe consequences in the Dutch enforcement and adjudication system. Supplemental materials are available for this article. Go to the publisher's online edition ofTraffic Injury Preventionto view the supplemental file. [ABSTRACT FROM PUBLISHER]

Published
2013
Full Text
View/download PDF

48. No evidence for the presence of HuD-specific T cells in the cerebrospinal fluid of patients with Huassociated paraneoplastic neurological syndromes.

Author

de Beukelaar, Janet W., Milikan, Johannes C., Verjans, Georges M., de Graaf, Marieke T., van Norden, Yvette, Lamers, Cor H., van den Bent, Martin J., Bromberg, Jacoline E., Hulsenboom, Esther, Sintnicolaas, Kees, Gratama, Jan W., and Smitt, Peter A. Sillevis

Subjects
LETTERS to the editor, CEREBROSPINAL fluid
Abstract

A letter to the editor is presented asserting that the cerebrospinal fluid of patients with Hu-associated paraneoplastic neurological syndromes does not contain HuD-specific T cells.

Published
2009
Full Text
View/download PDF

49. No evidence for circulating HuD-specific CD8+ T cells in patients with paraneoplastic neurological syndromes and Hu antibodies.

Author

de Beukelaar, Janet W., Verjans, Georges M., van Norden, Yvette, Milikan, Johannes C., Kraan, Jaco, Hooijkaas, Herbert, Sintnicolaas, Kees, Gratama, Jan W., and Sillevis Smitt, Peter A.

Subjects
PARANEOPLASTIC syndromes, T cells, ANTIGENS, SMALL cell lung cancer, BLOOD testing, NEURONS, SYNDROMES, PATIENTS, DISEASES
Abstract

In paraneoplastic neurological syndromes (PNS) associated with small cell lung cancer (SCLC) and Hu antibodies (Hu-PNS), Hu antigens expressed by the tumour hypothetically trigger an immune response that also reacts with Hu antigens in the nervous system, resulting in tumour suppression and neuronal damage. To gain more insight into the hypothesized CD8+ T cell-mediated immune pathogenesis of these syndromes, we searched for circulating HuD-specific CD8+ T cells in a large cohort of Hu-PNS patients and controls. Blood was tested from 43 Hu-PNS patients, 31 Hu antibody negative SCLC patients without PNS and 54 healthy controls. Peripheral blood mononuclear cells (PBMC) were stimulated with HuD protein-spanning peptide pools (15-mers) and individual HuD-derived peptides (9-mers) and analysed by cytokine flow cytometry and interferon-γ ELISPOT-assays. Additionally, HuD-based Class I HLA multimers were used to visualize HuD-specific CD8+ T cells. No HuD-specific CD8+ T cells could be detected in the blood of Hu-PNS patients or controls. Our results do not support a role for HuD-specific CD8+ T cells in Hu-PNS. Further studies should focus on the detection of circulating HuD-specific CD4+ T cells and examine the antigen specificity of T cells in affected tissues. [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results